Cathelicidin LL-37 for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Cathelicidin LL-37 for Health & Longevity

Created on 07/01/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

Cathelicidin LL-37 is the body's own microbe-killing, wound-healing peptide, switched on strongly by vitamin D. No oral form works and none is approved; the only reliable lever is keeping vitamin D sufficient. It is genuinely double-edged: too much drives inflammatory skin conditions, some autoimmune disease, and certain cancers. Best kept in healthy balance, not maximized. (Full Review)

Protocol

Lever
Vitamin D3 to sufficiency
Target 25(OH)D of ~30–50 ng/mL with cofactors magnesium and vitamin K2
Timing
Morning, with a fatty meal
Vitamin D3 taken with dietary fat for absorption; morning preferred by those sensitive to evening dosing
Frequency
Daily dosing
Daily vitamin D3 preferred over large intermittent boluses for steadier downstream induction
Time to effect
Innate immune support
Weeks to a few months
Time to raise 25(OH)D enough to meaningfully induce LL-37 via consistent vitamin D; downstream immune effect is gradual
Topical wound healing
Days to weeks
Directly applied LL-37 in investigational wound trials acts locally over this window

Benefits

Contraindications
  • Pregnancy and lactation (investigational LL-37)
  • Active psoriasis, rosacea, or systemic lupus erythematosus
  • Other LL-37-associated autoimmune disease
  • Cancers where LL-37 is tumor-promoting (ovarian, lung)
    •
Key Interactions
  • Vitamin D and vitamin D analogs (cholecalciferol, calcitriol, calcipotriol)
  • Immunosuppressants and biologics (corticosteroids, methotrexate)
  • OTC acne/rosacea topicals (benzoyl peroxide, azelaic acid)
  • LL-37-raising supplements (vitamin D3, vitamin K2, magnesium, boron, butyrate)
  • Sunlight/UV exposure and phototherapy
    •

Risk & Side Effects

  • Medium: Contribution to inflammatory skin disease; autoimmune activation
    •
  • Low: Local irritation and cytotoxicity from direct administration; pro-tumor effects in certain cancers
    •
  • Speculative: Atherosclerosis and vascular inflammation; disruption of the microbiome
    •

Monitoring

Marker Target Why
25-Hydroxyvitamin D (25(OH)D) 30–50 ng/mL Main driver of endogenous LL-37 production
High-Sensitivity C-Reactive Protein (hs-CRP) < 1.0 mg/L Detects body-wide inflammation that LL-37 excess can drive
Serum Calcium 9.0–10.0 mg/dL Safety check when using higher vitamin D doses to raise LL-37
Complete Blood Count (CBC) Within reference range Reflects neutrophil status, the main reservoir of LL-37
LL-37 / hCAP18 (research assay) Not clinically established Direct measure of the peptide itself

Cadence: Baseline before starting; re-check vitamin D at 8–12 weeks after starting or changing a dose, then every 6–12 months once stable, with skin and inflammatory review at similar intervals in susceptible individuals

Qualitative Assessment

  • Infection frequency and recovery: fewer or milder respiratory and skin infections
  • Skin condition: worsening rosacea flushing, papules, or psoriasis plaques may signal harmful LL-37 elevation
  • Energy and general wellbeing: subjective vitality alongside corrected vitamin D
  • Wound healing: faster wound closure in investigational topical use
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.